Evidence map›Paper›PMID 36360523›Full record

ArticleHealthcare (Basel, Switzerland)2022

Underreporting and Triggering Factors for Reporting ADRs of Two Ophthalmic Drugs: A Comparison between Spontaneous Reports and Active Pharmacovigilance Databases.

Homero Contreras-Salinas, Leopoldo Martín Baiza-Durán, Manuel Alejandro Bautista-Castro, Diego Rodrigo Alonso-Rodríguez, Lourdes Yolotzin Rodríguez-Herrera

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Homero Contreras-SalinasPharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Zapopan 45010, Jalisco, Mexico.ORCID 0000-0001-9918-2024
Leopoldo Martín Baiza-DuránPharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Zapopan 45010, Jalisco, Mexico.
Manuel Alejandro Bautista-CastroPharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Zapopan 45010, Jalisco, Mexico.
Diego Rodrigo Alonso-RodríguezPharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Zapopan 45010, Jalisco, Mexico.
Lourdes Yolotzin Rodríguez-HerreraPharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Zapopan 45010, Jalisco, Mexico.
Laboratorios Sophia (Mexico) · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Aims of the study: calculating the underreporting ratio for two different medications, a fixed combination of 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide (antiglaucoma) and a fixed combination of sodium hyaluronate 0.1% + chondroitin sulfate 0.18% (artificial tears) for characterizing the features influencing the reporting of adverse drug reactions (ADRs) in spontaneous reporting. (2) Methods: The underreporting ratio was calculated by comparing the adverse drug reactions reported in the spontaneous reporting database for every 10,000 defined daily doses marketed and the adverse drug reactions from an active surveillance study for every 10,000 defined daily doses used for different drugs (antiglaucoma and artificial tears). The factors related to the report in spontaneous reporting through statistical tests were also determined. (3) Results: The underreporting ratio of spontaneous reporting was 0.006029% for antiglaucoma and 0.003552% for artificial tears. Additionally, statistically significant differences were found for severity, unexpected adverse drug reactions, and incidence of adverse drug reactions in females when compared with spontaneous reporting and active surveillance. (4) Conclusions: The underreporting ratio of ADRs related to ophthalmic medications indicates worry since the cornerstone of pharmacovigilance focuses on spontaneous reporting. Additionally, since underreporting seems to b selective, the role of certain aspects, such as gender, seriousness, severity, and unexpected ADRs, must be considered in future research.

Indexed as

active surveillanceadverse drug reactionantiglaucomaartificial tearsspontaneous reportingunderreporting

Identifiers

PMID36360523
PMCPMC9690340
OpenAlexW4308119342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.